Keywords: AAV; adeno-associated viruses; Ad; adenovirus; CTGVT; cancer targeting gene-viro-therapy; EGFR; epidermal growth factor receptor; EPCs; endothelial precursor cells; GAOVT; gene armed oncolytic virus therapy; GCV; ganciclovir; HRE; hypoxia responsive eleme